Worldwide All Cap

Worldwide All Cap

An unconstrained investment strategy that invests in companies across the world which are positioned to contribute to, and benefit from, sustainable development.

Download overview
Important Note: I have read and agree, click to minimiseImportant Note: Click to maximise

This information is a financial promotion for the Stewart Investors Worldwide All Cap Strategy intended for professional clients only in Switzerland, the EEA and elsewhere where lawful.

Investing involves certain risks including:

  • The value of investments and any income from them may go down as well as up and are not guaranteed. Investors may get back significantly less than the original amount invested.
  • Currency risk: the Fund invests in assets which are denominated in other currencies; changes in exchange rates will affect the value of the Fund and could create losses. Currency control decisions made by governments could affect the value of the Fund's investments and could cause the Fund to defer or suspend redemptions of its shares.
  • Emerging market risk: Emerging markets tend to be more sensitive to economic and political conditions than developed markets. Other factors include greater liquidity risk, restrictions on investment or transfer of assets, failed/delayed settlement and difficulties valuing securities.

Where featured, specific securities or companies are intended as an illustration of investment strategy only, and should not be construed as investment advice or a recommendation to buy or sell any security.

For a full description of the terms of investment and the risks please see the Prospectus and Key Investor Information Document.

If you are in any doubt as to the suitability of our funds for your investment needs, please seek investment advice.

Our Worldwide All Cap strategy was launched in November 2012. It is an unconstrained investment strategy, by which we mean it is not restricted to certain countries, and is able to invest in between 40-60 companies all over the world. As with all of our strategies, we are interested in finding only the very best businesses; those with high quality management teams, franchises, and financials, that are well positioned to contribute to, and benefit from, sustainable development.

Strategy highlights: a focus on quality and sustainability

  • Companies must contribute to sustainable development. Portfolio Explorer >

  • We invest in high-quality companies with exceptional cultures, strong franchises and resilient financials. How we pick companies >

  • We avoid companies linked to harmful activities and engage and vote for positive change. Our position on harmful products >

  • Our approach is long-term, bottom-up, high conviction and benchmark agnostic

  • We focus on capital preservation as well as capital growth – we define risk as the permanent loss of client capital

Latest insights

Quarterly updates

Strategy update: Q3 2024

Worldwide All Cap strategy update: 1 July - 30 September 2024

The quarter has seen some market turbulence, driven by uncertainty over interest rates and geopolitical developments, as well as emerging questions over the ability of the largest technology stocks to continue their upwards trajectory. The strong focus on technology, and particularly artificial intelligence (AI), over the past year means that other sectors have been neglected. As a result, we believe there are many quality stocks that are now attractively priced for long-term growth, most of them addressing problems in the real world.

We bought four new positions during the quarter, all in the industrials sector, but with very different end customer markets and applications.

Rentokil Initial (United Kingdom: Industrials) is a global leader in pest control services, a necessary and critical health and hygiene service to secure homes, hospitals and businesses against disease and damage. Its business model is fundamentally local in nature and generates lots of cash through resilient, recurring sales. The management team is focused on growth by increasing the density of its route network, and so driving improvements in profitability and earnings.

Applied Industrial Technologies (United States: Industrials) is one of the largest distributors of industrial motion and control technologies in the United States. Its products are used in end applications such as power transmission, fluid power, flow control and other industrial processes that help its customers be more productive and efficient and do more with less. It has a strong brand, well-poised to leverage its scale and customer network for growth as the world becomes increasingly automated.

ESAB Corporation (United States: Industrials) sells gas control equipment, welding equipment and particularly the metal alloys that are required for welding. Welding is not only a foundation technology to support the modern world, without welding there would be no buildings or trains, but it also plays a key role in supporting the green transition through its use in wind turbines and other green infrastructure. Its strength in supplying the metal alloys means they generate a lot of cash from recurring sales, which supports its balance sheet and allows it to invest in new business opportunities.

1202078050

Simpson Manufacturing (United States: Industrials) make connectors, fastening systems, adhesives and speciality chemicals that connect, strengthen and support the joints within wooden and concrete structures. Its end customers are construction companies which rely on high-quality parts to comply with building codes and regulations. Its products make buildings stronger and safer, improving their ability to withstand extreme weather events, which are becoming more common as the planet warms.

The acquisitions were funded by two divestments during the quarter. Coloplast (Denmark: Health Care) makes ostomy bags and wound care products. We had started reducing the position last quarter due to valuation and decided to exit completely due to potential challenges facing a recent acquisition. Natura (Brazil: Consumer Staples) sells beauty and personal care products. We have held Natura in the strategy for many years as a company with long-term owners that embedded sustainability into their business model from the early days and had international expansion opportunities ahead of it. They acquired Avon in 2022 which ultimately proved more difficult to integrate and turn around than we anticipated, and we have taken the decision to invest in better opportunities elsewhere.

We are always looking at new companies and recently visited Sweden to meet with some new and some old businesses. These included Atlas Copco (Sweden: Industrials), the world's leading manufacturer of air compressors, and access solutions provider Assa Abloy (Sweden: Industrials), both of which are held in the strategy. The opportunity to meet with company management on their ‘home turf’ is invaluable; it is much easier to get a sense of how culture and people have shaped a company and its future return profile when sitting within their offices; or, in the case of Atlas Copco, 20 metres below their office in a test mine. We continue to find excellent investment ideas by focussing on the impact that outstanding people can have on businesses with strong franchises and resilient financials.

Case Study: Atlas Copco

Listing: Nasdaq Stockholm

Market cap: US$83bn1

Held in fund since: September 2020

Company description

Founded in 1873 to make products for Sweden’s railways, Atlas Copco is a multinational provider of industrial solutions including air compressors, vacuum pumps, and tools. It derives 70% of its sales from outside Europe.2

Why do we like it? / Investment rationale

Atlas Copco was named after the mythological Titan who carries the sky on his shoulders; such lofty etymology highlights the ambition, determination and passion that has driven this company over 151 years. Beginning with one of the three original founders of the business, André Wallenberg, Atlas Copco continues to be stewarded by the Wallenberg family, and benefitted from their support during two difficult periods in the 1880s and 1930s when the business pivoted from railway products to diesel motors and, finally, air compressors.

Atlas Copco’s end markets are well-diversified, ranging from manufacturers of semiconductors, automobiles, food and beverage, and pharmaceuticals. The product portfolio is formidable, but Atlas Copco’s key innovation was the development of energy-saving variable-speed drive compressors in 1994, which are still iterated today using new software and sensors to optimise performance. The latest version saves a further 11% of CO2 emissions compared to their predecessors, and as much as 90% of the energy used can be recovered for use in heating or steam.3 Further innovations in dry air compressors – critical in the manufacture of electronics – exemplify the rewards of Atlas Copco’s sustained research and development (R&D) spending, which was 4% of sales in 2023.4

As innovative as Atlas Copco’s new products are, their closeness to customers allows them to seize the opportunity of finding new applications for existing products such as the use of an oil-free air compressor to create ‘bubble curtains’ around offshore wind developments. This reduces underwater noise by over 90% to protect marine wildlife.5

Much of Atlas Copco’s innovation has been spurred by the decentralised model. This splits the business into divisions and smaller business units, which are entrusted with autonomy and accountability for their own profit-and-loss statement, as well as customer engagement. An internal job market and strong encouragement of internal mobility – including internationally – has built a strong culture, whether employees are based in Stockholm or Manila. Testament to this is the enduring tenure of both the CEO Vagner Rego (25 years) and the CFO Peter Kinnart (31 years).

With a relatively asset-light business model and outsourced manufacturing, Atlas Copco’s cash flows are stabilised by recurring servicing and aftermarket revenues. Ongoing acquisitions into new technologies should complement organic growth opportunities within industrial electrification and digitalisation, setting Atlas Copco up for another 150 years.

What could go wrong? / Risks

Atlas Copco faces the risk that worsening macroeconomic conditions may reduce customer budgets and propensity to spend. There is also the risk of intensifying competition from Chinese companies. 

1 As of 19.9.24.

2 CapIQ.

No waste - low emissons - Atlas Copco Group

Keeping it dry - Atlas Copco Group. R&D spend – S&P Capital IQ.

Oil-free bubble curtains protecting marine life - Atlas Copco UK.

Source for company information: Stewart Investors investment team and company data. This stock information does not constitute any offer or inducement to enter into any investment activity. Portfolio data shown is from representative strategy accounts of the strategy shown above. Named new investments disclosed relate to holdings with a portfolio weight over 0.5%. It is not a recommendation or solicitation to purchase or invest in any fund. Differences between the representative account-specific constraints, currency or fees and those of a similarly managed fund or mandate would affect results.

Download a PDF copy

Select Strategy update and/or Proxy voting to produce a report. You can then download a copy of the report by clicking on the button.

You can build a bespoke report for all our strategies on the full Quarterly update report.

Stewart Investors Quarterly Client Update Q3 2024

1 July - 30 September 2024

Quarter update

Risk factors

This material is a financial promotion for the Stewart Investors strategies – Asia Pacific and Japan All Cap, Asia Pacific Leaders, Asia Pacific All Cap, European All Cap, European (ex UK) All Cap, Global Emerging Markets All Cap, Global Emerging Markets Leaders, Indian Subcontinent All Cap, Worldwide All Cap and Worldwide Leaders – and is intended for professional clients only in the UK, Switzerland and EEA and professional clients elsewhere where lawful.

Within the EU/EEA and Switzerland, the European (ex UK) strategy is only available to investors via a segregated mandate account.

Investing involves certain risks including:

  • The value of investments and any income from them may go down as well as up and are not guaranteed. Investors may get back significantly less than the original amount invested.
  • Emerging market risk: Emerging markets tend to be more sensitive to economic and political conditions than developed markets. Other factors include greater liquidity risk, restrictions on investment or transfer of assets, failed/delayed settlement and difficulties valuing securities.
  • Indian Subcontinent risk: although India has seen rapid economic and structural development, investing there may still involve increased risks of political and governmental intervention, potentially limitations on the allocation of the strategy’s capital, and legal, regulatory, economic and other risks including greater liquidity risk, restrictions on investment or transfer of assets, failed/delayed settlement and difficulties valuing securities.
  • Specific region risk: investing in a specific region  may be riskier than investing in a number of different countries or regions. Investing in a larger number of countries or regions helps spread risk.
  • Currency risk: the strategies invest in assets which are denominated in other currencies; changes in exchange rates will affect the value of the strategies and could create losses. Currency control decisions made by governments could affect the value of the strategies’ investments and could cause the strategies to defer or suspend redemptions of shares.
  • Concentration risk: the European Sustainability and Worldwide Leaders Sustainability strategies referred to in this material invest in a relatively small number of companies which may be riskier than a strategy that invests in a large number of companies.
  • Smaller companies risk: investments in smaller companies may be riskier and more difficult to buy and sell than investments in larger companies.

Where featured, specific securities or companies are intended as an illustration of investment strategy only, and should not be construed as investment advice or a recommendation to buy or sell any security.

If you are in any doubt as to the suitability of our strategies for your investment needs, please seek investment advice.

Investment philosophy

  • We are stewards: Our role is to allocate society’s capital to productive uses, in accordance with our Hippocratic Oath
  • We are long term: Our time horizon is measured in years, not weeks, and we value companies accordingly
  • We invest only in companies contributing to a more sustainable future: We engage constructively as owners to help companies on their sustainability journeys
  • We invest only in high-quality companies: We seek out companies with exceptional cultures, strong franchises and resilient financials
  • We believe capital preservation is important for capital growth: We define risk as the possibility of the permanent loss of client capital

Investment objective

To generate attractive long-term, risk-adjusted returns by investing in the shares of high-quality companies that are particularly well positioned to contribute to, and benefit from sustainable development.

Important information

This material is for general information purposes only. It does not constitute investment or financial advice and does not take into account any specific investment objectives, financial situation or needs. This is not an offer to provide asset management services, is not a recommendation or an offer or solicitation to buy, hold or sell any security or to execute any agreement for portfolio management or investment advisory services and this material has not been prepared in connection with any such offer. Before making any investment decision you should conduct your own due diligence and consider your individual investment needs, objectives and financial situation and read the relevant offering documents for details including the risk factors disclosure. Any person who acts upon, or changes their investment position in reliance on, the information contained in these materials does so entirely at their own risk.

We have taken reasonable care to ensure that this material is accurate, current, and complete and fit for its intended purpose and audience as at the date of publication but the information contained in the material may be subject to change thereafter without notice.

No assurance is given or liability accepted regarding the accuracy, validity or completeness of this material.

To the extent this material contains any expression of opinion or forward-looking statements, such opinions and statements are based on assumptions, matters and sources believed to be true and reliable at the time of publication only. This material reflects the views of the individual writers only. Those views may change, may not prove to be valid and may not reflect the views of everyone at First Sentier Investors.

Past performance is not indicative of future performance. All investment involves risks and the value of investments and the income from them may go down as well as up and you may not get back your original investment. Actual outcomes or results may differ materially from those discussed. Readers must not place undue reliance on forward-looking statements as there is no certainty that conditions current at the time of publication will continue. 

References to specific securities (if any) are included for the purpose of illustration only and should not be construed as a recommendation to buy or sell the same. Any securities referenced may or may not form part of the holdings of First Sentier Investors’ portfolios at a certain point in time, and the holdings may change over time.

References to comparative benchmarks or indices (if any) are for illustrative and comparison purposes only, may not be available for direct investment, are unmanaged, assume reinvestment of income, and have limitations when used for comparison or other purposes because they may have volatility, credit, or other material characteristics (such as number and types of securities) that are different from the funds managed by First Sentier Investors.

Selling restrictions

Not all First Sentier Investors products are available in all jurisdictions.

This material is neither directed at nor intended to be accessed by persons resident in, or citizens of any country, 

or types or categories of individual where to allow such access would be unlawful or where it would require any registration, filing, application for any licence or approval or other steps to be taken by First Sentier Investors in order to  comply with local laws or regulatory requirements in such country.

About First Sentier Investors

References to ‘we’, ‘us’ or ‘our’ are references to First Sentier Investors, a global asset management business which 

is ultimately owned by Mitsubishi UFJ Financial Group (MUFG). Certain of our investment teams operate under the trading names FSSA Investment Managers, Stewart Investors and Realindex Investments, all of which are part of the First Sentier Investors Group.

This material may not be copied or reproduced in whole or in part, and in any form or by any means circulated without the prior written consent of First Sentier Investors.

We communicate and conduct business through different legal entities in different locations. This material is communicated in:

  • United Kingdom by First Sentier Investors (UK) Funds Limited, authorised and regulated by the Financial Conduct Authority (reg. no. 2294743; reg office Finsbury Circus House, 15 Finsbury Circus, London EC2M 7EB).
  • European Economic Area by First Sentier Investors (Ireland) Limited, authorised and regulated in Ireland by the Central Bank of Ireland (CBI reg no. C182306; reg office 70 Sir John Rogerson’s Quay, Dublin 2, Ireland; reg company no. 629188).
  • Other jurisdictions, where this document may lawfully be issued, by First Sentier Investors International IM Limited, authorised and regulated in the UK by the Financial Conduct Authority (reg. no. 122512; reg office 23 St. Andrew Square, Edinburgh, EH2 1BB; regcompany no. SC079063).

To the extent permitted by law, MUFG and its subsidiaries are not liable for any loss or damage as a result of reliance on any statement or information contained in this document. Neither MUFG nor any of its subsidiaries guarantee the performance of any investment products referred to in this document or the repayment of capital. Any investments referred to are not deposits or other liabilities of MUFG or its subsidiaries, and are subject to investment risk, including loss of income and capital invested.

© First Sentier Investors Group

Strategy update: Q2 2024

Worldwide All Cap strategy update: 1 April - 30 June 2024

“We want to help lift the whole industry up”1.

Advanced Drainage Systems (United States: Industrials) are the second largest plastics recycler in the US but they want to do more. They are investing in a grinding facility and considering investments in sorting technology, which would improve margins and make plastic recycling more attractive to other companies.

We recently visited the United States to meet with a wide range of industrial and consumer companies across Chicago, Cincinnati, Columbus, Cleveland, Boston and New York. In total we met with 50 companies, many of them leaders in their industries. We highlight some of the companies we met with in more detail here along with reasons why we believe they fit so well with our investment approach. The trip was a great reminder of the number of excellent companies out there with competent and ethical stewards that generate returns by focusing on building long-term franchises in profitable niches.

During the quarter we added three new positions. Ashtead Group (United Kingdom: Industrials) is an industrial and construction equipment rental company that derives the majority of its revenues from the United States. The franchise has high returns and opportunities for strong growth prospects given the fragmented nature of the equipment rental market. Roper Technologies (United States: Information Technology) owns, buys and builds software companies that are leaders in their niches. This business model generates strong cashflows that can be used to buy more businesses, setting it up to continue to generate cashflows well in the future. TopBuild (United States: Consumer Discretionary) is the largest installer and distributor of insulation in North America. They are well positioned to grow from acquiring smaller businesses in another fragmented market and building economies of scale, supported by the growing need for more energy efficient homes and commercial buildings.

We continue to be vigilant about valuations and this is reflected in our decision to divest completely from seven positions. Three of these were from companies that, in our view, had reached rich valuations: Fisher & Paykel Healthcare (New Zealand: Health Care), Admiral (United Kingdom: Financials) and Marico (India: Consumer Staples). We divested from bioMérieux (France: Health Care) to consolidate the exposure to life sciences and from Kotak Mahindra Bank (India: Financials) to consolidate our exposure to Indian banks which are facing a more competitive environment. We divested from Synopsys (United Kingdom: Information Technology) and from Spirax Group (United Kingdom: Industrials) due to concerns about ongoing risks to their respective franchises coupled with valuations that left no room for error.

During the quarter, one of our companies was targeted by an activist investor who was concerned that it was overbuilding manufacturing capacity. Their concerns were based on near-term revenue expectations in an industry that is expected to grow by multiples in the coming years. We disagreed as the company’s record of counter cyclical and industry leading investments has handsomely rewarded patient shareholders and we wrote to offer them our support.

The market concentration we highlighted last quarter shows no sign of abating with continuing excitement about any company connected with building Artificial Intelligence (AI) infrastructure. We do not have any insight into how new technologies work through an economy nor where the main revenues or profits will appear. Instead of allowing ourselves to be distracted by a single growth driver, we seek to build a portfolio of companies that can benefit from a wide range of diverse growth drivers, as we believe that this is the best way to protect and grow our clients’ capital over the long term.

1 Source: Stewart Investors investment team, June 2024

 

Case Study: Roche

Listing: Swiss Market Index

Market cap: US$221bn

Shareholders since: September 2022

Company description

Founded in 1896 by Fritz Hoffman-La Roche, Roche is a multi-national healthcare company that produces pharmaceutical drugs, as well as diagnostic equipment and reagents. In 2023, its medicines treated 22 million patients worldwide and its diagnostic systems 29 billion test results.3

Why do we like it? / Investment rationale

One hundred and thirty years on from its foundation, Roche continually finds new ways to meet patient need. The ownership of the Hoffman and Oeri families empowers Roche to pursue decade-long opportunities; that Roche has had just seven CEOs in 125 years is testament to their long-term outlook.

Roche is industry-leading in its research & development (R&D) spend at 26% of pharmaceutical sales – almost USD15 billion4– and has produced blockbuster drugs in areas as diverse as neurology, oncology, and immunology. Their multiple sclerosis drug Ocrevus, for example, has over 25% share in the United States5; a recent formulation allows treatment by injection rather the original 4-hour infusion, saving patient and healthcare professionals’ time.6 Roche’s sustained investment in drug development has built a diversified pipeline of over 100 drugs, with nine in final phase testing7. Nor is Roche averse to finding new development methods; their gene therapy subsidiary, Genentech, has entered a strategic collaboration with Nvidia using artificial intelligence to maximise drug discovery opportunities within Roche’s extensive datasets.8

The pharmaceutical business has been strengthened by Roche’s market-leading diagnostics segment, which offers strong recurring revenues from the sale of consumables as well as equipment. Roche currently offers 600 tests and plans to launch a further 40 each year9. Long-term structural trends guide investment and development; Roche’s new, automated mass spectrometry systems (measuring the characteristics of chemical samples) should enable laboratories to perform more sensitive tests without hiring highly specialised technicians to operate complex machinery. Similarly, Roche has pioneered one of the first regulatory-approved10, self-administered cervical swabs to address low uptake of cervical cancer screening; an innovative solution that hopefully reduces the 4,000 annual, preventable deaths from cervical cancer in the United States, and many thousands more in middle- and low-income countries.11

Roche’s true opportunity lies at the intersection of its unique expertise across diagnostics, data, and drug development: personalised medicine, enabling earlier detection of illness, individualised treatment, and better patient monitoring. With its consistently strong balance sheet and strong cash flow generation – with cash flows growing at an average compound rate of 20% over the last 20 years12 – we believe Roche is ready to seize the opportunity.

What could go wrong? / Risks

Roche faces the risk of failures within its drug pipeline, although its extent and diversification, as well as the diagnostics segment, should cushion the impact of any one failure. Similarly, technological disruption could affect Roche’s business, despite its strong position in R&D investment.

3 Roche factsheet, 2023

4 Source: Stewart Investors investment team and company data

5 Source: Stewart Investors investment team and company data

Subcutaneous Ocrevus gets approval in EU for forms of MS (multiplesclerosisnewstoday.com).

7 Source: Stewart Investors investment team and company data

Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development | Business Wire

9 Source: Stewart Investors investment team and company data

10 Approved in the United States by the Food and Drug Administration (FDA)

11 Press release by Roche on cervical swab approval, 2024

12 S&P Capital IQ.

Source for company information: Stewart Investors investment team and company data. This stock information does not constitute any offer or inducement to enter into any investment activity. Portfolio data shown is from representative strategy accounts of the strategy shown above. Named new investments disclosed relate to holdings with a portfolio weight over 0.5%. It is not a recommendation or solicitation to purchase or invest in any fund. Differences between the representative account-specific constraints, currency or fees and those of a similarly managed fund or mandate would affect results.

Strategy update: Q1 2024

Worldwide All Cap strategy update: 1 January - 31 March 2024

The market continues to look very concentrated, particularly for any company connected to Artificial Intelligence (AI). And, while the Magnificent 7 is no more as the likes of Tesla and Apple have slowed, NVIDIA, Microsoft and Meta continue to climb. Although we do not hold these companies, we are excited about the possibilities of AI to contribute to innovative solutions and drive human development, as reflected in some new positions in the portfolio.

During the quarter we added new positions in both TSMC (Taiwan: Information Technology) and Samsung Electronics (South Korea: Information Technology). Both companies are fabricating the chips that are designed by AI companies and are an essential part of the semiconductor value chain. They are also both well run with strong growth prospects and reasonable valuations. And it is not only in the developed world that increasing data, digitalisation and connectivity will be driving opportunities for growth. We entered a position in Tata Communications (India: Communication Services) as we also see exciting prospects for these structural growth drivers in India. We also added to Elisa (Finland: Communication Services) to take advantage of reasonable valuations and EPAM Systems (United States: Information Technology) as we continue to build our conviction in them.

We completely divested three portfolio companies. Cochlear (Australia: Health Care) remains a high-quality sustainability company and our decision to sell was prompted by concerns about its valuation compared to its growth prospects. We sold Cognex (United States: Information Technology) and Alfen (Netherlands: Industrials) due to concerns about their ability to weather more challenging end market environments ahead.

Controlling the portfolio sizes of companies also raised cash for new positions. These fell into three broad areas: Firstly, trimming the size of top ten holdings which have run up in price including Fortinet (United States: Information Technology), Beiersdorf (Germany: Consumer Staples), bioMérieux (France: Health Care) and Admiral (United Kingdom: Financials). Secondly, we are watching the emerging competitive environment facing Indian banks and controlling our exposure by reducing our position in Kotak Mahindra Bank (India: Financials).

Thirdly, we continued to take some profits from our position in Adyen (Netherlands: Financials). This stock has been exposed to the full force of market irrationality over the last six month and its price fell by over half in August when it slightly missed earnings growth expectations. We took the opportunity to add several times over the next few months before the price started to increase again. We then trimmed twice during the quarter to take profits and control the position size, but we retain conviction in the quality of its franchise and growth runway ahead.

As we head further into 2024, there remains little consensus around whether inflation will continue to fall or rise further, whether interest rates will remain where they are or be cut, or whether we are heading into a stronger or weaker economy. However outside of the stock market we are seeing some return to normality. Companies that we meet with are welcoming the end of a phase of de-stocking that was brought about by the supply chain issues and overstocking of 2022 and are looking forward to a return to more typical growth trends. We remain as reticent as ever to predict the path of macroeconomic variables, instead, focusing on finding high-quality companies supported by a diverse range of structural growth drivers, with strong balance sheets and competent management to take advantage of them.

Case Study: Fortinet

Listing: NASDAQ

Market cap: US$51bn

Shareholders since: July 2019

Company description

Founded in 2000 by brothers Ken and Michael Xie, Fortinet is one of the largest global providers of network security hardware and software. These solutions support customers across a highly diversified set of geographies, industries and customers. In 2023, their Fortiguard services offering blocked 2.4trn vulnerability attempts and 3bn malware deliveries to protect customers.1

Why do we like it? / Investment rationale

Fortinet’s strength lies within its founders’ expertise, patience, and ambition. Together, Ken and Michael have almost 50 years of experience in network security. They had the foresight as early as the late 1990s to invest in the design and manufacture of firewall-specific processing chips (application-specific-integrated-circuit, or ASICs).

When compared to firewalls run on general-purpose computing processors, Fortinet’s ASIC-based firewalls operate more quickly and efficiently, allowing them to block more complex threats from accessing the network. Not only do Fortinet’s chips offer better performance at lower power requirements (-88% vs. industry-standard processing chips), reducing the overall cost of ownership for customers, but vertical integration helps them secure chips, even during recent supply chain snarls in which some competitors experienced months-long shipping delays.

This technical expertise has helped Fortinet build a strong franchise across a highly diversified customer base, with its single biggest country exposure being the US at 27% of sales. More predictable services revenues now amount to 60% of sales, while Fortinet has grown free cash flow at a compounded average growth rate of 27% since 2015. Pleasingly, the Xie brothers’ long-termism has seen much of this bolster a balance sheet which has more cash than debt. They have also been able to invest cash flows into research & development, and have invested  $1.7 billion to this end since 2017. This investment underpins Fortinet’s ambitions to grow further through end-to-end network security solutions – protecting infrastructure, data, access and applications.

As such, Fortinet is well-placed to capitalise on structural tailwinds around our economy’s increasing dependence on computing networks to connect data, devices, and people – fanned further by the possibilities of broader AI adoption – but also the mounting risks posed by cyberattacks. Some estimates suggest global cybercrime costs could hit $10.5 trillion dollars by 20252, to say nothing of less-easily quantified reputational risks or consequences of state-sponsored attacks on critical infrastructure. In an increasingly uncertain world, Fortinet’s technical expertise and patient investment offers customers the protections they need to seize the digitalisation opportunity.

What could go wrong? / Risks

Fortinet itself faces the risk of cyberattacks and technological disruption, although we feel these are mitigated by their R&D investment and expertise. Similarly, deteriorating macro-economic conditions could pressure customer budgets and push out cybersecurity investments, although recurring revenues and cash generation should help Fortinet weather short-term demand weakness.

 

1 Fortiguard Outbreak Alerts Annual Report 2023

2 2022 Official Cybercrime Report by Cybersecurity Ventures: https://www.esentire.com/resources/library/2022-official-cybercrime-report

Reference to the names of each company mentioned in this material is merely for explaining the investment strategy and should not be construed as investment advice or investment recommendation.

Source for company information: Stewart Investors investment team and company data. This stock information does not constitute any offer or inducement to enter into any investment activity. Portfolio data shown is from representative strategy accounts of the strategy shown above. Named new investments disclosed relate to holdings with a portfolio weight over 0.5%. It is not a recommendation or solicitation to purchase or invest in any fund. Differences between the representative account-specific constraints, currency or fees and those of a similarly managed fund or mandate would affect results.

Strategy update: Q4 2023

Worldwide All Cap strategy update: 1 October - 31 December 2023

The strategy performed well in Q4, resulting in a positive return for the full year. However, it was another turbulent year, following on from the travails of 2022, leading to a challenging environment for most portfolio companies and fluctuations in portfolio performance.

In 2022, Russia’s invasion of Ukraine led to a short-term boom in energy prices and a longer-term rise in geo-political tensions which have continued throughout 2023. Also during 2022, many companies had to cope with supply chain challenges, which led to overstocking in many instances and contributed to higher inflation. Throughout 2023, de-stocking and slowing demand was a common challenge, along with interest rates that in many countries ended the year approximately five times higher than they were at the start of 2022.

The period between August and October was particularly challenging as many macroeconomic concerns came to a head. At other times the overall market was buoyant, but this was largely driven by United States mega-cap tech stocks and fashionable themes such as artificial intelligence (AI) and weight loss drugs. Outside a very narrow range of stocks, the threat of recession, uncertainty over central bank actions and the increasingly pessimistic outlook from China put downward pressure on the valuations of small and mid-cap stocks and on many European-listed stocks. Against this backdrop and an increasingly concentrated market, the dispersion of returns was wide and there were some sharp drawdowns in the share prices of some portfolio companies.

An example was Adyen (Netherlands: Financials) whose price fell by 60% in August1 after it missed its growth estimates. This occurred at a time when the business was investing for the long-term, by increasing their headcount, which reduced their profit margins in the short term. We retained our conviction in the management team, business model and opportunity for the company and added to our position twice in October.

Fortinet (United States: Information Technology) also experienced a large price drawdown after its annual earnings were slightly lower than estimates due to clients shifting orders from June to July2 and worries of a slow-down in their core market of secure networking. However, the company is pivoting to faster growing security operations and universal Secure Access Service Edge (SASE) segments and has achieved consistently resilient growth over many years. It is forecast to grow by 25% a year for the next few years and we remain convinced it offers an excellent long-term investment opportunity. We took the opportunity to add to our position at attractive valuations.

We made no new additions to the portfolio in Q4 but increased positions in several companies with resilient cash flows on compelling valuations, including Halma (United Kingdom: Industrials), Spectris (United Kingdom; Information Technology) and Edwards Lifesciences (United States: Healthcare). We also added to companies that had become deeply out of favour but which have sound fundamentals and are well set up to benefit from tailwinds in automation, in the case of Zebra Technologies (United States: Industrials), and the energy transition, in the case of Alfen (Netherlands: Industrials).

Valuations also played a role in decisions to trim positions in Admiral (United Kingdom: Financials), Arista Networks (United States: Information Technology) and Advanced Drainage Systems (United States: Industrials). And we completely divested from Constellation Software (Canada: Information Technology) due to high valuations. While we retain conviction in its management and business model, its valuation left no room for error and we feel there are better opportunities elsewhere.

The most disappointing aspect of performance over the last two years has been the negative contribution from healthcare companies. As well as their contribution to human development, we expect them to be resilient and steady compounders of value over the long term. Our sense is that many of them have weathered the storm of post-pandemic de-stocking and are well-placed to grow as the sector normalises.

As always, we remain focused on buying companies with high-quality management teams and exceptional franchises that are driving human development and alleviating environmental pressures. Our portfolio is well diversified, not only across sectors and geographies, but also growth drivers such as improving energy efficiency, the rise of living standards in India and the growth of diagnostics. With portfolios of high-quality, great sustainability companies bought at reasonable valuations, we are excited about the future.

1 Source: S&P Capital IQ
2 Source: S&P Capital IQ

Source for company information: Stewart Investors investment team and company data. This stock information does not constitute any offer or inducement to enter into any investment activity. Portfolio data shown is from representative strategy accounts of the strategy shown above. Named new investments disclosed relate to holdings with a portfolio weight over 0.5%. It is not a recommendation or solicitation to purchase or invest in any fund. Differences between the representative account-specific constraints, currency or fees and those of a similarly managed fund or mandate would affect results.

Proxy voting

Proxy voting: Q3 2024

Worldwide All Cap proxy voting: 1 July - 30 September 2024

Proxy voting by country of origin

Proxy voting by proposal category

During the quarter there were 88 resolutions from seven companies to vote on.  On behalf of clients, we voted against seven resolutions.

We voted against the appointment of the auditor at Advanced Drainage Systems as they have been in place for over ten years. The company has given no information on intended rotation which we believe is important for ensuring a fresh perspective on the accounts. (one resolution)

We voted against remuneration motions at Ashtead Group as we were concerned about excesses in CEO salary. (two resolutions)

We voted against proposals related to amendments to articles (rules and regulations that govern the company's operations) at DiaSorin as the company did not provide enough information on the amendments. (three resolutions*)

We voted against the appointment of the auditor at Vitasoy as they have been in place for over ten years. The company has given no information on intended rotation which we believe is important for ensuring a fresh perspective on the accounts. (one resolution)

*The same proposal was voted on different stock lines.

Source for company information: Stewart Investors investment team and company data. This stock information does not constitute any offer or inducement to enter into any investment activity. Portfolio data shown is from representative strategy accounts of the strategy shown above. Proxy voting chart numbers may not add to 100 due to rounding. SHP means: Shareholder Proposal.

Proxy voting: Q2 2024

Worldwide All Cap voting: 1 April - 30 June 2024

Proxy voting by country of origin

Proxy voting by proposal category

During the quarter there were 446 resolutions from 32 companies to vote on. On behalf of clients, we voted against 26 resolutions.

We voted against the appointment of the auditor at A.O. Smith, Arista Networks, Edwards Lifesciences, EPAM Systems, Fortinet, Markel, Roper Technologies, Spirax Group, Synopsys, Texas Instruments, Veeva Systems and Zebra Technologies as they have been in place for over 10 years and the companies’ have given no information on intended rotation. We believe rotating an auditor on a relatively frequent basis (e.g. every 5-10 years) helps to ensure a fresh pair of eyes are examining the accounts, and follows best practice. (12 resolutions)

We voted against remuneration motions at Assa Abloy as we believe acquisitive businesses should incentivise management on returns as well as shares held. (two resolutions)

We voted against recasting of votes at Natura as we wish to avoid the election of potentially unknown nominees.  We voted against a remuneration proposal which the company highlighted was based on a discrepancy in our third-party research, misrepresenting the underlying proposal. Unfortunately it was too late to reverse the vote. We have alerted our research provider to the error. (two resolutions)

We voted against a proposal regarding transaction of business at Tecan as the company provided no detail on the proposal and we wish to avoid unfettered discretion. (one resolution)

We voted against an amendment to officer exculpation at Veeva Systems as we are not in favour of limiting the responsibility of corporate officers. (one resolution)

We voted against recasting and cumulative voting at WEG as this would allow the board to make changes without shareholder assessment or knowledge of candidates. (three resolutions)

We abstained from voting on requests for a separate board election and the election of a Supervisory Council position at WEG due to insufficient information and our preference for the current family stewards to remain in place. (two resolutions)

We voted against the decision to grant a one-off executive award with short vesting conditions at Zebra Technologies as we did not see sufficient rationale to support it. (one resolution)

We voted against a shareholder proposal at A.O. Smith requesting the company report on hiring practices for people with arrest records as we do not deem it necessary or productive and support the company's hiring process. (one resolution)

We voted against a shareholder proposal regarding board declassification at EPAM Systems as we do not deem it necessary for all directors to stand for election annually and believe this could destabilise the board by allowing excessive turnover. (one resolution)

We voted against a shareholder proposal regarding greenhouse gas (GHG) emissions disclosure at Markel as the proposal called for disclosure of emissions from underwriting, insuring and investments, which is not yet widely or reliably reported in the industry, hence we would prefer to discuss the issue with the company. (one resolution)

We abstained from voting on a shareholder proposal to remove supermajority requirements for certain issues at Roper Technologies as the board didn't provide a recommendation. (one resolution)

We voted against a shareholder proposal mandating an independent director serve as Chair at Synopsys as we are confident in the stewardship of the current Chair and former CEO to lead the majority independent board. (one resolution)

We voted for shareholder proposals regarding the right to call a special meeting and requesting a report on customer due diligence at Texas Instruments as we found both to be sensible. (two resolutions)

Source for company information: Stewart Investors investment team and company data. This stock information does not constitute any offer or inducement to enter into any investment activity. Portfolio data shown is from representative strategy accounts of the strategy shown above. Proxy voting chart numbers may not add to 100 due to rounding. SHP means: Shareholder Proposal.

Proxy voting: Q1 2024

Worldwide All Cap proxy voting: 1 January - 31 March 2024

Proxy voting by country of origin

Proxy voting by proposal category

During the quarter there were 126 resolutions from 10 companies to vote on.  On behalf of clients, we voted against 7 resolutions.

We voted against the appointment of the auditor at Nordson and Roche as they have each been in place for over 10 years. We believe rotating an auditor on a relatively frequent basis (e.g. every 5-10 years) helps to ensure a fresh pair of eyes are examining the accounts and follows best practice. We also voted against excessive executive renumeration at Roche. (seven resolutions)

Source for company information: Stewart Investors investment team and company data. This stock information does not constitute any offer or inducement to enter into any investment activity. Portfolio data shown is from representative strategy accounts of the strategy shown above. Proxy voting chart numbers may not add to 100 due to rounding. SHP means: Shareholder Proposal.

Proxy voting: Q4 2023

Worldwide All Cap proxy voting: 1 October - 31 December 2023

Proxy voting by country of origin

Proxy voting by proposal category

During the quarter there were 42 resolutions from five companies to vote on. On behalf of clients, we didn't vote against any resolutions.

Source for company information: Stewart Investors investment team and company data. This stock information does not constitute any offer or inducement to enter into any investment activity. Portfolio data shown is from representative strategy accounts of the strategy shown above. Proxy voting chart numbers may not add to 100 due to rounding. SHP means: Shareholder Proposal.

Portfolio Explorer

If you are unable to view the portfolio explorer, please re-open in Google Chrome, Edge, Firefox, Safari or Opera. IE11 is not supported.

For illustrative purposes only. Reference to the names of example company names mentioned in this communication is merely for explaining the investment strategy and should not be construed as investment advice or investment recommendation of those companies. Companies mentioned herein may or may not form part of the holdings of Stewart Investors. Holdings are subject to change.

Certain statements, estimates, and projections in this document may be forward-looking statements. These forward-looking statements are based upon Stewart Investors’ current assumptions and beliefs, in light of currently available information, but involve known and unknown risks and uncertainties. Actual actions or results may differ materially from those discussed. Readers are cautioned not to place undue reliance on these forward-looking statements. There is no certainty that current conditions will last, and Stewart Investors undertakes no obligation to correct, revise or update information herein, whether as a result of new information, future events or otherwise.

Source: Stewart Investors investment team and company data. Securities mentioned are all investee companies* from representative Asia Pacific All Cap Strategy, Asia Pacific & Japan All Cap Strategy, Asia Pacific Leaders Strategy, European All Cap Strategy, European (ex UK) All Cap Strategy, Global Emerging Markets (ex China) Leaders Strategy, Global Emerging Markets Leaders Strategy, Global Emerging Markets All Cap Strategy, Indian Subcontinent All Cap Strategy, Worldwide All Cap Strategy and Worldwide Leaders Strategy accounts as at 30 September 2024. *Assets that the strategies may hold which an active decision has not been made, and sustainability assessment does not apply, include cash, cash equivalents, short-term holdings for the purpose of efficient portfolio management and holdings received as a result of mandatory corporate actions. Holdings of such assets will not appear on Portfolio Explorer.

The Stewart Investors supports the Sustainable Development Goals (SDGs). The full list of SDGs can be found on the United Nations website.

Source for Climate Solutions and impact figures: © 2014–2024 Project Drawdown (drawdown.org). Source for Human Development Pillars: Stewart Investors investment team.

Source for climate solutions and human development analysis and mapping: Stewart Investors investment team. Contributions are defined by the team as demonstrable contributions to any solution, either direct (directly attributable to products, services or practices provided by that company), or enabling (supported or made possible by products or technologies provided by that company).

Investment terms

View our list of investment terms to help you understand the terminology within this document.

Fund data and information

Fund prices and details

Click on the links below to access key facts, literature, performance and portfolio information for the funds and share classes available in this jurisdiction:

Stewart Investors Worldwide All Cap Fund

Overview of Stewart Investors Worldwide All Cap Fund performance

Fund name Fund type Currency Price Daily change Price date Factsheet
Stewart Investors Worldwide All Cap Class III (Acc) Irish UCITs CAD 11.42 1.12 09 Dec 2024
Stewart Investors Worldwide All Cap Class I (Acc) Irish UCITs EUR 14.26 0.46 09 Dec 2024
Stewart Investors Worldwide All Cap Class VI (Acc) Irish UCITs EUR 3.02 0.46 09 Dec 2024
Stewart Investors Worldwide All Cap Class VI (Dist) Irish UCITs EUR 14.08 0.46 09 Dec 2024
Stewart Investors Worldwide All Cap Class VI (Acc) Irish UCITs GBP 13.32 0.35 09 Dec 2024
Stewart Investors Worldwide All Cap Class VI (Acc) Irish UCITs USD 10.38 0.44 09 Dec 2024
Stewart Investors Worldwide All Cap Class VI (Dist) Irish UCITs USD 10.25 0.44 09 Dec 2024

Share prices are calculated on a forward pricing basis which means that the price at which you buy or sell will be calculated at the next valuation point after the transaction is placed. Where a fund price is marked XD, this means that the fund is currently Ex-Dividend. Past performance is not necessarily a guide to future performance. The value of shares and income from them may go down as well as up and is not guaranteed. Please note that the yield quoted above is not the historic yield. It is considered that the yield quoted represents the current position of investments, income and expenses in the fund and that this is a more accurate figure. Investors may be subject to tax on their distribution. The yield is not guaranteed or representative of future yields. You should be aware that any currency movements could affect the value of your investment. The Funds within the First Sentier Investors Global Umbrella Fund plc (Irish VCC) are denominated in USD or EUR.

Following the UK departure from the European Union, the First Sentier Investors ICVC, an open ended investment company registered in England and Wales ("OEIC") has ceased to qualify as a UCITS scheme and is instead an Alternative Investment Fund ("AIF") for European Union purposes under the terms of the Alternative Investment Fund Managers Directive (2011/61/EU). Accordingly, no marketing activities relating to the OEIC are being carried out by Stewart Investors in the European Union (or the additional EEA states) and the OEIC is not available for distribution in those jurisdictions. We have made documents available for existing EU investors in the ICVC which can be accessed here

Strategy and fund name changes

As of end of 2024, please note that Stewart Investors strategies and the Funds within the UK First Sentier Investors ICVC and First Sentier Investors Global Umbrella Fund plc (Irish VCC) have been renamed. Please refer to note below for further information.